Intech Investment Management LLC increased its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 232.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,934 shares of the company's stock after purchasing an additional 11,834 shares during the quarter. Intech Investment Management LLC's holdings in Apogee Therapeutics were worth $767,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $71,000. Aigen Investment Management LP purchased a new position in shares of Apogee Therapeutics during the fourth quarter valued at approximately $216,000. Commonwealth Equity Services LLC acquired a new stake in Apogee Therapeutics during the fourth quarter worth approximately $222,000. Wexford Capital LP purchased a new stake in Apogee Therapeutics in the 3rd quarter worth approximately $230,000. Finally, Arizona State Retirement System raised its holdings in Apogee Therapeutics by 17.3% in the 4th quarter. Arizona State Retirement System now owns 6,517 shares of the company's stock valued at $295,000 after acquiring an additional 960 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.
Wall Street Analyst Weigh In
APGE has been the topic of several analyst reports. Citigroup assumed coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective on the stock. Wedbush reissued an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $92.17.
View Our Latest Report on Apogee Therapeutics
Apogee Therapeutics Trading Down 2.2 %
NASDAQ:APGE traded down $0.89 on Thursday, hitting $39.25. 523,402 shares of the stock were exchanged, compared to its average volume of 477,929. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $69.40. The stock has a market cap of $1.77 billion, a PE ratio of -16.22 and a beta of 2.46. The stock has a fifty day moving average of $37.47 and a 200-day moving average of $46.11.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). As a group, analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.
Insider Activity at Apogee Therapeutics
In other news, CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total value of $732,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,309,487 shares in the company, valued at approximately $63,968,439.95. This represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Carl Dambkowski sold 1,590 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the completion of the transaction, the insider now directly owns 251,033 shares of the company's stock, valued at $7,651,485.84. This represents a 0.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,195 shares of company stock worth $2,026,392. 36.10% of the stock is currently owned by corporate insiders.
About Apogee Therapeutics
(
Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Further Reading
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
